<?xml version="1.0" encoding="UTF-8"?>
<fig id="Fig4">
 <label>Fig. 4</label>
 <caption>
  <p>FACT-MM TOI change from pre-ASCT baseline values (adjusted). FACT-MM TOI scale is 0 to 112. 
   <bold>a</bold> Any maintenance therapy (solid line) versus no maintenance therapy (dashed line). 
   <bold>b</bold> Lenalidomide-only maintenance therapy (solid line) versus no maintenance therapy (dashed line). 
   <bold>c</bold> HRQoL at baseline, pre-ASCT, during follow-up, and at PD 
   <italic>P</italic> values are paired 
   <italic>t</italic> test comparisons between periods within treatment group. The TOI is the sum of the physical well-being, functional well-being, and "additional concerns‚Äù subscores. Autologous stem cell transplant (ASCT), Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM), health-related quality of life (HRQoL), lenalidomide (LEN), least-squares (LS), progressive disease (PD), trial outcome index (TOI). 
   <sup>a</sup>LS mean during the analysis period, 
   <sup>b</sup>66 patients had PD, 
   <sup>c</sup>45 patients had PD, 
   <sup>d</sup>44 patients had PD
  </p>
 </caption>
 <graphic xlink:href="277_2018_3446_Fig4_HTML" id="MO4" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
